PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of archdischfnLink to Publisher's site
 
Arch Dis Child Fetal Neonatal Ed. Nov 2007; 92(6): F498–F502.
PMCID: PMC2675405
Patent ductus arteriosus: lack of evidence for common treatments
Carl L Bose and Matthew M Laughon
Carl L Bose, Matthew M Laughon, Division of Neonatal‐Perinatal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
Correspondence to: Carl L Bose
Division of Neonatal‐Perinatal Medicine, CB#7596, UNC Hospital, Chapel Hill, NC 27599‐7596, USA; cbose@med.unc.edu
Accepted November 22, 2006.
Abstract
Patent ductus arteriosus (PDA) is a common diagnosis among extremely premature infants, especially in those with lung disease. Treatments are often used to close the PDA. Despite nearly three decades of research, the question of whether the benefits of treatments to prevent ductal patency or promote closure outweigh the risks of these treatments remains unanswered. The authors rarely use treatments designed to close the PDA. This article reviews three considerations in support of this restrained approach: rates of spontaneous closure of the ductus arteriosus; adverse effect of persistent ductal patency; and benefits and risks of treatments for closure.
Keywords: patent ductus arteriosus, indomethacin, ibuprofen, ductal ligation
Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of
BMJ Group